[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sickle-cell-anaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sickle-cell-anaemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100573194","hypoxic-red-blood-cells-in-sickle-cell-anemia-100573194",false,"NCT06743113","Hypoxic Red Blood Cells in Sickle Cell Anemia","A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia","Inclusion Criteria:\n\n1. Male or female at least 7 years of age;\n2. Are able to provide informed consent, and assent as applicable, to participate in the study;\n3. Diagnosis of Sickle Cell Anemia (SCA) (HbSS, HbSβ0 thalassemia) with participation in a chronic transfusion program and have undergone regular transfusions during at least 6 months prior to Screening;\n4. Have had an average interval of at least 14 days between RBC transfusions over the past 6 months;\n5. If on iron chelation therapy, have been on a stable dose for ≥3 months prior to screening;\n\nExclusion Criteria:\n\n1. Are not exclusively transfused at the site;\n2. Have a diagnosis of HbSC disease, HbSβ+ thalassemia or another SCD variant (excluding HbSS and HbSβ0 thalassemia)\n3. Are routinely transfused with washed, packed RBC units;\n4. Have received hemoglobin inducers (e.g. erythropoietin) in the 30 days prior to Screening;\n5. Are currently being evaluated for gene therapy;\n6. Have any clinically significant pulmonary, cardiovascular, endocrine, hepatic, gastrointestinal, renal, infectious, immunological (including significant allo- or auto-immunization) disease, considered not adequately controlled prior to the study;\n7. Are a female of child-bearing potential who is pregnant or planning to become pregnant in the next 14 months;\n8. Have a history of allo-immunization that cannot be managed by the local blood bank;\n9. Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol;\n10. Is a ward of the state, prisoner, or transient","ALL","7 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"NA","The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.",[26,27,28,29],"Sickle Cell Anaemia","Sickle Cell Anemia Crisis","Sickle Cell Anemia in Children","Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)","NOT_YET_RECRUITING","2026-01-06",{"date":33,"type":34},"2026-01-07","ACTUAL",{"date":36,"type":20},"2026-03",{"date":38,"type":20},"2028-09",{"name":40,"class":41},"Hemanext","INDUSTRY",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100614639","phase-2-efficacy-and-safety-of-sil-8301-for-control-of-hemolysis-in-a-uniform-sickle-cell-disease-endotype-100614639","NCT07282210","Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of SIL-8301 in Sickle Cell Disease (SCD) Patients With a Predominantly Hemolytic Phenotype","RESCUE","Inclusion Criteria:\n\n* Documented diagnosis of sickle cell disease\n* 16-35 years of age\n* Hb ≤ 9.0 g\u002FdL\n* History of no more than 1 acute SCD-related painful crises requiring a visit to a medical facility per year within the preceding 2 years\n* History of at least one hemolytic complication\n* Current treatment with hydroxyurea\n\nExclusion Criteria:\n\n* Receipt of senicapoc in a previous investigational study\n* Current Red Blood Cell (RBC) transfusion or exchange transfusion program\n* History of pulmonary hypertension\n* Active cardiovascular, neurologic, endocrine, hepatic, or renal disorders\n* Diagnosis of cancer (except non-melanoma skin cancer in situ, cervical cancer in situ, or breast cancer in situ) within the last 5 years\n* History of liver disease","16 Years","35 Years",{"count":54,"type":20},105,[56],"PHASE2","SIL-8301 (senicapoc) is being developed for the chronic treatment of patients with sickle cell disease in both adults and children. The purpose of this study is to compare the effects of senicapoc to placebo in patients with sickle cell disease that have had fewer than 2 acute sickle-related painful crises per year over the preceding 2 years, and have a predominantly hemolytic phenotype, defined as presence or history of at least one hemolytic complication and a baseline Hb of 9 g\u002FdL or less, despite receiving hydroxyurea (an oral drug used for treatment of sickle cell disease) as standard of care. Participants will take senicapoc or matching placebo daily and continue on hydroxyurea as prescribed for up to 24 weeks.",[59,26,60],"Sickle Cell Disease","Sickle Cell Anemia",[62,63,64,65,66,67,68,69,70,71,72],"senicapoc","Anemia, Hemolytic, Congenital","Anemia, Hemolytic","Anemia","Hematologic Diseases","Hemic and Lymphatic Diseases","Hemoglobinopathies","Genetic Diseases, Inborn","Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Anemia, Sickle Cell","Anaemia, Sickle Cell","2025-12-01",{"date":75,"type":34},"2025-12-15",{"date":77,"type":20},"2026-01",{"date":79,"type":20},"2029-01",{"name":81,"class":41},"Biossil Inc.",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":91,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100562340","the-relationship-of-platelet-counts-with-sickle-cell-anemia-in-the-eastern-region-of-saudi-arabia-100562340","NCT06601894","The Relationship of Platelet Counts With Sickle Cell Anemia in the Eastern Region of Saudi Arabia","Inclusion criteria: All the diagnosed patients of sickle cell disease regardless of age and gender.\n\nExclusion criteria: Patients without having sickle cell disease regardless of age and gender.","1 Year",{"count":90,"type":20},650,"1 Month","OBSERVATIONAL","This study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the Kingdom of Saudi Arabia.",[26,95],"SCD","2024-10-03",{"date":98,"type":34},"2024-10-04",{"date":100,"type":20},"2024-12-01",{"date":102,"type":20},"2025-03-30",{"name":104,"class":105},"Majmaah University","OTHER",1]